Technology | Clinical Decision Support | April 30, 2018

Point of Care Decision Support Releases New Version of Anticoagulation Software

Clinical decision support software version 2.0 adds new features, improves performance and supports CMS reimbursement requirements

Point of Care Decision Support Releases New Version of Anticoagulation Software

Image courtesy of Point of Care Decision Support

April 30, 2018 — Point of Care Decision Support (PCDS) announced the release of a new version 2.0 of their anticoagulation clinical decision support (CDS) software. The application was developed with leading clinical thrombosis experts to specifically address the new and complex challenges of managing both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs). It enables healthcare provider teams to deliver consistent, measurable and evidence-based quality of care for patients on anticoagulants.

Key benefits to healthcare practitioners that electronically document care for patients on an oral anticoagulant therapy include:

  • Central patient dashboard that allows them to understand the patient's history and plan in less than 60 seconds;
  • Automatic dosage calculations using validated nomograms to assist in medication management;
  • Integration with validated survey instruments such as CHA2DS2-VASc, HAS-BLED and HEMORR2HAGES;
  • Full patient plan of care instructions available to print, providing a customized and relevant shared patient/clinician experience;
  • Electronic medical record (EMR)-agnostic integration with bidirectional flow of patient data that dramatically decreases data entry; and
  • Enhanced reporting options that meet Centers for Medicare and Medicaid Services (CMS)/Medicare Access and CHIP Reauthorization Act (MACRA) "high activity" improvement requirements.

PCDS demonstrated AC 2.0 at the AC Forum Boot Camp for physicians, nurses and pharmacists that work with patients on oral anticoagulant therapies, April 23-24 in Austin, Texas.

For more information: www.ptofcare.com

 

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...